Is dextromethorphan safe during breastfeeding?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Dextromethorphan Safety in Breastfeeding

Dextromethorphan is generally considered safe during breastfeeding, with minimal infant exposure through breast milk and a relative infant dose of less than 1% of the maternal dose. 1

Evidence Supporting Safety

The FDA drug label advises breastfeeding mothers to "ask a health professional before use," which reflects a cautious but not prohibitive stance. 2 However, the available pharmacokinetic data provides reassurance about actual infant exposure levels.

Infant Exposure Data

  • A pharmacokinetic study in 20 lactating women taking a single 30 mg dose of dextromethorphan found that infant exposure was estimated at only 0.33 ± 0.32 μg/kg/day for dextromethorphan and 1.8 ± 1.0 μg/kg/day for its active metabolite dextrorphan. 1

  • At steady-state dosing (60 mg twice daily), the estimated infant exposure remained low at 0.64 ± 0.22 μg/kg/day for dextromethorphan and 1.23 ± 0.38 μg/kg/day for dextrorphan. 1

  • The relative infant dose (RID) was calculated to be less than 1%, which is well below the generally accepted safety threshold of 10% for medication use during breastfeeding. 1

Pharmacokinetic Properties

  • Dextromethorphan and dextrorphan distribute extensively into breast milk, with milk-to-plasma ratios of 1.0 and 1.6 respectively, but the absolute amounts transferred remain clinically insignificant. 1

  • The dose received by infants via breast milk is generally much smaller than known safe doses of medications given directly to neonates and infants. 3

Important Caveats

Isolated Adverse Event Report

  • One nursing infant in the pharmacokinetic study developed an erythematous rash during maternal dextromethorphan use, though causality was not definitively established. 1

  • This single case warrants monitoring infants for potential skin reactions, though it does not contraindicate breastfeeding. 1

General Safety Profile

  • Dextromethorphan has been used for over 30 years with a reassuring safety profile showing infrequent and usually non-severe adverse reactions. 4

  • The predominant symptoms when adverse events occur are dose-related and include neurological, cardiovascular, and gastrointestinal disturbances. 4

Clinical Recommendations

Breastfeeding mothers may use dextromethorphan at recommended doses without interrupting nursing. 1

  • Use the lowest effective dose for the shortest duration necessary to control cough symptoms. 2

  • Monitor the infant for unusual sedation, irritability, or skin rashes, though these are unlikely at therapeutic maternal doses. 1

  • Avoid exceeding recommended doses, as the safety profile is dose-dependent. 4

  • Do not use if taking monoamine oxidase inhibitors (MAOIs), as this represents a significant drug interaction risk regardless of breastfeeding status. 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.